Every day, Sanofi employees work to chase the miracles of science and improve people’s lives by asking themselves “what if?” Our work is rooted in scientific curiosity centered on the question: What if we could evolve expectations for people living with rare blood disorders?
Jeff Schaffnit
Head of U.S. Rare Blood Disorders, Sanofi
Sanofi’s approach to scientific innovation is foundational to our ability to serve the rare blood disorder community and offer hope now and in the future. By focusing on first-in-class and best-in-class treatments and vaccines, we aim to change the practice of medicine for the better. At Sanofi, patients and science are at the center of everything we do.
Listening and learning from rare blood disorder communities
For more than a decade, we’ve been continually inspired by the strength and resilience of the rare blood disorder community. And we understand that we cannot help improve patient’s lives without listening to them, their care partners, their advocates, and their doctors:
“I’d gone through a very stressful period of time in my life and really ignored the symptoms. … The bloodwork came back and he said, ‘I need you to clear your schedule. I think it’s ITP,’” said Tracey, a person living with immune thrombocytopenia (ITP).
“Living with hemophilia is a love-hate relationship. It does limit your ability. Even though it’s closed down some avenues, it’s forced me to open up new ones,” said Julian, a person living with hemophilia.
“I stayed in the hospital for four weeks. I was told I had a rare deadly blood disorder called TTP. There was no cure,” said Anise, a person living with acquired thrombotic thrombocytopenic purpura (aTTP).
But words become more powerful when we can take these insights and turn them into action. With greater insight into the impact these conditions have on the daily life of patients and their care partners, we can work together to build a brighter future.
History of breaking treatment barriers
Patient insights and stories help drive our ongoing curiosity of scientific innovation. In 2014, we launched the first extended half-life factor replacement therapies for people with hemophilia A and B, marking significant innovations in hemophilia management.
More recently, we pioneered a first-in-class, high-sustained factor VIII replacement therapy that is elevating treatment expectations for people with hemophilia A, regardless of age. But we’re not done pushing the boundaries of innovation in hemophilia, as we continue to explore new approaches.
Our dedication to the rare blood disorder community also includes people with immune-mediated conditions that have limited treatment options. Sanofi launched the first and only FDA-approved treatments for a life-threatening condition called acquired thrombotic thrombocytopenic purpura (aTTP),1 as well as cold agglutinin disease (CAD). We are also committed to research in immune thrombocytopenia (ITP) where there is an ongoing unmet need. We will never stop innovating and we are determined to transform the standard of care for all people affected by rare blood disorders.
To hear patient stories and learn more information about Sanofi, please visit rareblooddisorders.com
References
- Mancini, I, et al. Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopaenic Purpura: Fourteen Years of the Milan TTP Registry. Thromb Haemost. 2019;119(5):695-705.
MAT-US-2400456-v1.0-02/2024. © 2024 Genzyme Corporation. All rights reserved.